Active Ingredient History
Secukinumab, sold under the brand name Cosentyx, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alopecia Areata (Phase 2)
Arthritis (Phase 3)
Arthritis, Juvenile (Phase 3)
Arthritis, Psoriatic (Phase 4)
Arthritis, Rheumatoid (Phase 4)
Asthma (Phase 2)
Autoimmune Diseases (Phase 2)
Axial Spondyloarthritis (Phase 4)
Behcet Syndrome (Phase 3)
Biopsy (Phase 4)
Carcinoma, Giant Cell (Phase 3)
Colorectal Neoplasms (Phase 1/Phase 2)
COVID-19 (Phase 2)
Crohn Disease (Phase 2)
Dermatitis, Allergic Contact (Phase 3)
Dermatitis, Atopic (Phase 2)
Diabetes Mellitus, Type 1 (Phase 2)
Dry Eye Syndromes (Phase 2)
Giant Cell Arteritis (Phase 2)
Graves Ophthalmopathy (Phase 3)
Healthy Volunteers (Phase 4)
Hidradenitis Suppurativa (Phase 3)
Hyperkeratosis, Epidermolytic (Phase 2)
Ichthyosiform Erythroderma, Congenital (Phase 2)
Ichthyosis (Phase 4)
Ichthyosis, Lamellar (Phase 2)
Inflammation (Phase 4)
Inflammatory Bowel Diseases (Phase 2)
Lichen Planus (Phase 2)
Lupus Erythematosus, Discoid (Phase 2)
Lupus Nephritis (Phase 3)
Metabolic Syndrome (Phase 4)
Multiple Sclerosis (Phase 2)
Multiple Sclerosis, Relapsing-Remitting (Phase 2)
Necrobiosis Lipoidica (Phase 2)
Netherton Syndrome (Phase 2)
Non-alcoholic Fatty Liver Disease (Phase 3)
Non-Radiographic Axial Spondyloarthritis (Phase 3)
Pharmacokinetics (Phase 1)
Pityriasis Rubra Pilaris (Phase 1)
Polymyalgia Rheumatica (Phase 2)
Premature Ejaculation (Phase 1)
Psoriasis ()
Pyoderma Gangrenosum (Phase 2)
Rosacea (Phase 1/Phase 2)
Spondylarthritis (Phase 4)
Spondylarthropathies (Phase 3)
Spondylitis (Phase 3)
Spondylitis, Ankylosing (Phase 4)
Substance Withdrawal Syndrome (Phase 3)
Tendinopathy (Phase 2)
Uveitis (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
